Citations

Clear

1893 citation(s) found for "Wu, Kenneth".

American Foregut Society White Paper on the Endoscopic Assessment of the Gastroesophageal Valve After Anti-Reflux Surgery
Nguyen, Ninh T. , Bell, Reginald , Chang, Kenneth J. , Lipham, John C. , Hinojosa, Marcelo W. , Brunaldi, Vitor , Dunst, Christy M. , Mittal, Ravinder K., Oelschlager, Brant K. , Houghton, Caitlin, Schnoll‐Sussman, Felice , Kahrilas, Peter J., Dayyeh, Barham K. Abu , Buckley, Francis Paul, Kahrilas, Peter J.

Mayo Clinic

Foregut: The Journal of the American Foregut Society | November 20, 2024 | Volume: 5 | Issue: 2 | Pages: 95-106

10.1177/26345161241300480 Get It

Background: Pathologic reflux is a common debilitating digestive condition and anti-reflux surgery is an effective treatment option. Depending on the specifics of the procedure, anti-reflux surgery leads to distinct changes in the endoscopic appearance of the esophagogastric junction (EGJ). This American Foregut Society (AFS) white paper develops nomenclature for describing the endoscopic characteristics of the EGJ after commonly performed laparoscopic antireflux operations. Methods: The AFS Anti-Reflux Barrier Collaborative analyzed the anatomic manipulation and corresponding endoscopic appearance of the EGJ after commonly performed anti-reflux surgery including: (1) 360° anterior/posterior (AP) fundoplication (Nissen); (2) posterior partial fundoplication (Toupet); (3) anterior partial fundoplication (Watson, Dor); (4) magnetic sphincter augmentation; and (5) concomitant hiatal hernia repair with transoral fundoplication (cTIF). Results: Characteristics common to the anti-reflux surgery procedures include restoration of intra-abdominal esophageal length and crural diaphragm repair such that the hiatal aperture is no longer visible in the retroflexed endoscopic view. With regard to the geometry of anti-reflux procedures, the Collaborative established that when evaluated endoscopically in retroflection, the surgically constructed valve should be described in reference to the angle of His and the extent of anatomic change described in terms of (1) the depth of the anterior and posterior grooves, (2) the apposition of the valve collar to the endoscope, (3) the length of the valve, and (4) the position of the squamocolumnar junction relative to the lip of the valve. Conclusions: Current anti-reflux operations share much in common but employ varying degrees of valvular reconstruction leading to distinct endoscopic characteristics. Developing a consistent nomenclature for describing the appearance of the post-surgical valve is essential to develop a better understanding of how variables such as the tightness of the hiatal repair, tightness of the valve collar, and length of the valve can impact the outcome of anti-reflux surgery and predict reflux recurrence.
Association Between Tibiofemoral Bone Shape Features and Retears After Anterior Cruciate Ligament Reconstruction
Bailey, Karsyn N. , Gao, Kenneth T. , Halvorson, Ryan T. , Oeding, Jacob F. , Majumdar, Sharmila, Pedoia, Valentina , Oeding, Jacob F , Lansdown, Drew Anderson

Mayo Clinic

Orthopaedic Journal of Sports Medicine | November 19, 2024 | Volume: 12 | Issue: 11 | Pages: No page available

10.1177/23259671241289096 | PMID 39569414 Get It

Background: A retear after anterior cruciate ligament (ACL) reconstruction remains a common and devastating complication. Knee bone morphology is associated with the risk of ACL injuries, ACL retears, and osteoarthritis, and a combination of tools that derive bone shape from clinical imaging, such as magnetic resonance imaging (MRI) and statistical shape modeling, could identify patients at risk of developing these joint conditions. Purpose: To identify bone shape features before primary ACL reconstruction in patients with an eventual retear compared to those with a known intact ACL graft. Study Design: Case-control study; Level of evidence, 3. Methods: Bone was automatically segmented on 2-dimensional proton density–weighted MRI of the knee in patients at the time of the initial ACL injury using deep convolutional neural networks. Patients with a subsequent retear after reconstruction within 3 years (22 femurs, 19 tibias) were compared with those with an intact ACL graft at 3 years (20 femurs, 22 tibias) using statistical shape modeling to identify preoperative bone shape features predictive of a retear after ACL reconstruction. Results: Statistical shape modeling revealed 2 specific bone shape features (modes) in the femur and 1 mode in the tibia that demonstrated significant differences at the time of the initial injury in patients with subsequent retears. In the femur, a narrower intercondylar notch width, a widened medial condylar width, an increased femoral condylar offset ratio, increased surface area along the lateral femoral condyle relative to the medial condyle, and a more prominent trochlear sulcus at the time of the initial injury were associated with retears after ACL reconstruction. In the tibia, a diminished ACL facet prominence, a squared lateral and medial tibial plateaus, and a broader and flattened tibial spine at the time of the initial injury were associated with retears after ACL reconstruction. Conclusion: Using the automatic bone segmentation pipeline on preoperative MRI, the authors identified bone shape features associated with a retear after ACL reconstruction. The use of this pipeline enables large-scale studies of bone shape on MRI and could predict patients at risk of ACL retears to alter treatment decisions.
Unipolar Voltage Mapping to Predict Recovery of Left Ventricular Ejection Fraction in Patients With Recent-Onset Nonischemic Cardiomyopathy
Chaumont, Corentin , Peyster, Eliot , Siontis, Konstantinos C. , Muser, Daniele , Markman, Timothy M. , Pathak, Rajeev K. , Oraii, Alireza, Rodríguez-Queraltó, Oriol , Anselme, Frédéric , Peyster, Eliot G , Kapa, Suraj , Markman, Timothy M , Pathak, Rajeev K , Anselme, Frédéric , Marchlinski, Francis E , Muser, Daniele , Kapa, Suraj , Oraii, Alireza , Margulies, Kenneth B. , Marchlinski, Francis E. , Frankel, David S.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 151 | Issue: 6 | Pages: 368-378

10.1161/circulationaha.124.070501 | PMID 39540275 Get It

BACKGROUND: The ability to predict recovery of left ventricular ejection fraction (LVEF) in response to guideline-directed therapy among patients with nonischemic cardiomyopathy is desired. We sought to determine whether left ventricular endocardial unipolar voltage measured during invasive electroanatomic mapping could be used to predict LVEF recovery among those with recent-onset nonischemic cardiomyopathy. METHODS: We analyzed the left ventricular voltage maps of patients included in the eMAP trial (Electrogram-Guided Myocardial Advanced Phenotyping; NCT03293381), a prospective, nonrandomized, interventional trial conducted at 2 institutions between 2017 and 2020. Patients had recent-onset nonischemic cardiomyopathy defined by LVEF ≤45% and development of symptoms or signs of heart failure within the past 6 months. Detailed voltage maps of the left ventricular endocardium were generated using the Carto electroanatomic mapping system. Abnormal unipolar amplitude was defined as <8.27 mV. The primary end point was recovery of LVEF (Recovery) defined by a 1-year LVEF ≥50% or ≥45% with ≥10% increase from baseline. RESULTS: Of the 29 enrolled patients (median age, 49 years [25th percentile, 39; 75th percentile, 59], 8 females [27.6%]), LVEF recovered in 13 (44.8%) by 1-year follow-up. The percentage of total endocardial surface area with unipolar voltage abnormality (AUA) was significantly lower among Recovery patients than No Recovery patients (18.2% [25th percentile, 6.4; 75th percentile, 22.4] versus 80.0% [25th percentile, 29.5; 75th percentile, 90.9]; P =0.004). Percent AUA was associated with lower likelihood of Recovery (odds ratio, 0.64 per 10% increase in AUA; 95% CI, 0.47–0.88; P =0.006). A 28% cutoff value for percent AUA was 92% sensitive and 75% specific with an area under the receiver operating characteristic curve of 0.81 (95% CI, 0.63–0.99; P =0.001) for predicting recovery versus no recovery. The majority of patients (12 of 13; 92.3%) with a percent AUA >28% did not recover. CONCLUSIONS: Left ventricular unipolar voltage abnormality is a potent predictor of LVEF recovery among patients recently diagnosed with nonischemic cardiomyopathy. Detailed left ventricular unipolar voltage mapping could therefore be used as a valuable prognostic tool in guiding treatment decisions.
Abstract 4135873: Time Course of Late Gadolinium Enhancement Intensity in Ventricular Myocardium after Proton Beam Irradiation in Swine
Deisher, A., Newman, Laura K. , Kruse, Jon J. , Shumway, Dean A. , Merrell, Kenneth W. , Packer, D. L., Siontis, Konstantinos C. , Rettmann, Maryam E. , Koya, Taro , Hirao, Tatsuhiko

Mayo Clinic

Circulation | November 13, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4135873 Get It

Background: Proton beam irradiation to the ventricular myocardium may enable non-invasive targeting of ventricular tachycardia. Previous work has demonstrated the feasibility of imaging ablation lesion with late gadolinium enhanced (LGE) cardiac magnetic resonance imaging (MRI). Hypothesis: We hypothesize that proton beam irradiation will lead to progressively increasing density of LGE corresponding to lesion formation during follow-up after treatment delivery. Aim: The aim of the current study was to determine the time course of LGE intensity in ventricular myocardium following proton beam therapy. Methods: Eleven swine were irradiated with 40 Gy proton beam in the anterior or lateral left ventricular (LV) followed by LGE cardiac MRI every 4 weeks for up to 24 weeks. After manual contouring of the endocardial and epicardial myocardium, a region of interest (ROI) in the area irradiated with 0-5 Gy was contoured (remote ROI). The mean and standard deviation (SD) of the signal intensity (SI) of the remote ROI were calculated. Light LGE was defined as voxels with SI > mean+2SD but < mean+3SD of the remote ROI, while voxels with SI > mean+3SD of the remote ROI were classified as having dense LGE. Voxels identified as bright due to image artifacts or noise were manually removed. The analysis was conducted in a fashion blinded to swine ID and time point after irradiation. Results: A total of 33 time points were analyzed (3.1 ± 1.4 MRI studies per swine). Figure 1A shows a representative time course of LGE in the same swine, progressing from diffuse light LGE at 8 weeks to dense LGE at 16-24 weeks. Figure 1B demonstrates the proportion of light versus dense LGE across timepoints in irradiated myocardial regions. At 8 weeks, light and dense LGE areas were evenly distributed. At 12 to 24 weeks, dense LGE increased to approximately 75%. The proportion of dense versus light LGE was significantly higher at 12, 16, and 24 weeks, as compared to 8 weeks. Conclusion: In ventricular myocardium, diffuse light LGE evident at 8 weeks progresses to denser LGE at 12-24 weeks following proton beam irradiation corresponding with lesion formation.
BIOM-71. EXPANDING THE SPECTRUM OFTERT PROMOTER NON-CANONICAL SEQUENCE VARIANTS IN CNS TUMORS: A CASE SERIES
Trejo‐Lopez, Jorge , Saha, Neiladri , Koganti, Tejaswi , Hardcastle, Jayson, Smoley, Stephanie A., Isaacson, Matthew, Gandham, Mallika , Sivasankaran, Gopinath, Dasari, Surendra , Fung, Kar‐Ming, Powell, Suzanne Z., Trivedi, Darshan, Abdullaev, Zied , Aldape, Kenneth , Quezado, Martha , Edgar, Mark , Jenkins, Robert B. , Cook, David, Pitel, Beth A. , Isaacson, Matthew, Pratt, Drew , Cimino, Patrick J. , Vaubel, Rachael A. , Raghunathan, Aditya , Giannini, Caterina , Ida, Cristiane M.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii36-viii36

10.1093/neuonc/noae165.0143 Get It

Abstract Most TERT promoter (TERTp) clinically relevant sequence variants in CNS tumors are the canonical C228T and C250T mutations. Non-canonical TERTp mutations have been reported mainly in non-CNS tumors. We describe 12 CNS tumors with non-canonical TERTp variants interpreted as clinically relevant. Using clinical targeted NGS panels (2020-2024), we detected c.-100_-79dup (n=2), c.-92_-91insGGCGGCCCCGCCCCTTCCTTTC (n=1), c.-118_-117insTCCCCGGCCCAGCCCCTTCCGGG (n=1), c.-123_-76dup (n=1), c.-110_-89dup (n=2), and c.-57A&gt;C (n=5). Most cases had chromosomal microarray (n=11) and/or methylation array data analyzed using the NCI/Bethesda v.2 classifier (n=9). All non-canonical TERTp variants occurred at a variant allele frequency suggestive of somatic clonal origin (mean, 34%; range, 18-46), and in adults (mean age, 60 years; range, 36-88). Except for the c.-57A&gt;C variant, all non-canonical TERTp variants occurred in tumors with histological and/or molecular diagnostic features of glioblastoma, IDH-wildtype (GBM), often epigenetically aligning to this tumor type. All five tested cases matched to superfamily glioblastoma (score ≥ 0.9), with three to class GBM_RTK_I (&gt;0.9 in 2, 0.86 in 1) and two to GBM_RTK_II (&gt;0.9). The size and sequence of such variants suggest that these may be functionally equivalent to canonical mutations or generate favorable TERTp activation motif conformations like previously reported activating duplications. The c.-57A&gt;C variant is a well-established oncogenic mutation observed in other cancer types but has not been reported in CNS tumors. We describe five cases with the c.-57A&gt;C variant: one GBM matching to methylation class GBM_MES_TYP (0.99); two oligodendroglioma, IDH-mutant and 1p/19q-codeleted, one of which had methylation data matching to class O_IDH (0.99); one diffuse glioma, IDH-mutant, which was partially 1p/19q-codeleted and matched to class O_IDH (0.99); and one anaplastic meningioma, aligning to superfamily meningioma (0.99)/MNG_MAL (0.79). Our findings show that non-canonical TERTp variants typically occur in tumor types that often harbor TERTp canonical mutations, expanding the spectrum of TERTp clinically relevant variants that are molecular biomarkers in CNS tumors.
Vestibular Schwannoma Koos Grade I International Study of Active Surveillance Versus Stereotactic Radiosurgery: The VISAS-K1 Study
Bin-Alamer, Othman , Peker, Selçuk , Samancı, Yavuz , Pelcher, Isabelle , Begley, Sabrina , Goenka, Anuj , Schulder, Michael , Tourigny, Jean-Nicolas, Hamel, Andréanne, Briggs, Robert G. , Yu, Cheng , Zada, Gabriel , Giannotta, Steven L., Palque, Sarai, Kumar, Narendra , Rogowski, Brandon, Shepard, Matthew J., Warnick, Ronald E. , Dayawansa, Sam , Vasconcellos, Fernando De Nigris , Bernstein, Kenneth , Sheehan, Jason P. , Johnson, Bryan A, Sheehan, Jason , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Mathieu, David , Giannotta, Steven L. , Speckter, Herwin , Tripathi, Manjul , Kumar, Saurabh , Kaur, Rupinder , Johnson, Bryan A., Trifiletti, Daniel M. , Mashiach, Elad , Schnurman, Zane , Alzate, Juan Diego , Kondziolka, Douglas

Mayo Clinic

Neurosurgery | November 6, 2024 | Volume: 96 | Issue: 1 | Pages: 41-49

10.1227/neu.0000000000003215 | PMID 39503441 Get It

BACKGROUND AND OBJECTIVE: This investigation evaluates the safety and efficacy of stereotactic radiosurgery (SRS) vs observation for Koos grade I vestibular schwannomas (VS). METHODS: In a multicenter study, we retrospectively analyzed data of patients with Koos grade I VS who underwent SRS (SRS group) or were observed (observation group). Propensity score matching was used to equilibrate demographics, tumor size, and audiometric data across groups. The outcome analyzed included tumor control, preservation of serviceable hearing, and neurological function. RESULTS: The study matched 142 patients, providing a median follow-up period of 36 months. SRS significantly enhanced tumor control compared with observation, with a 100% control rate at both 5- and 8-year marks in the SRS group vs 48.6% and 29.5% in the observation group at the same time intervals, respectively ( P < .001). Preservation of serviceable hearing outcomes between groups showed no significant difference at 5 and 8 years, ensuring a comparable quality of auditory function (SRS 70.1% vs observation 53.4% at 5 years; P = .33). Furthermore, SRS was associated with a reduced likelihood of tinnitus (odds ratio [OR] = 0.46, P = .04), vestibular dysfunction (OR = 0.17, P = .002), and overall cranial nerve dysfunction (OR = 0.49, P = .03) at last follow-up. CONCLUSION: SRS management of patients with Koos grade I VS was associated with superior tumor control and reduced odds for cranial nerve dysfunction, while not compromising hearing preservation compared with observation. These findings support the safety and efficacy of SRS as a primary care approach for this patient population.
Vestibular Schwannoma Koos Grade II International Study of Active Surveillance Versus Stereotactic Radiosurgery: The VISAS-K2 Study
Bin-Alamer, Othman , Peker, Selçuk , Samanci, Yavuz, Pelcher, Isabelle , Begley, Sabrina , Goenka, Anuj , Schulder, Michael , Tourigny, Jean-Nicolas, Hamel, Andréanne, Briggs, Robert G. , Yu, Cheng , Zada, Gabriel , Giannotta, Steven L., Palque, Sarai, Kumar, Narendra , Rogowski, Brandon, Shepard, Matthew J., Warnick, Ronald E. , Dayawansa, Sam , Vasconcellos, Fernando De Nigris , Bernstein, Kenneth , Sheehan, Jason P. , Samancı, Yavuz , Johnson, Bryan A, Sheehan, Jason , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Mathieu, David , Giannotta, Steven L. , Speckter, Herwin , Tripathi, Manjul , Kumar, Saurabh , Kaur, Rupinder , Johnson, Bryan A., Trifiletti, Daniel M. , Mashiach, Elad , Schnurman, Zane , Alzate, Juan Diego , Kondziolka, Douglas

Mayo Clinic

Neurosurgery | November 6, 2024 | Volume: 96 | Issue: 1 | Pages: 50-58

10.1227/neu.0000000000003216 | PMID 39503444 Get It

BACKGROUND AND OBJECTIVES: This study assessed the efficacy and safety of stereotactic radiosurgery (SRS) in comparison with watchful waiting for managing Koos grade II vestibular schwannomas (VS). METHODS: A retrospective, multicentric analysis was conducted, focusing on patients with Koos grade II VS who either received SRS (SRS group) or were observed (observation group). To ensure comparability between groups, propensity score matching was used, including factors such as demographic characteristics, tumor dimensions, and hearing assessments. The primary end points examined were tumor control, maintenance of serviceable hearing, and neurological outcomes. RESULTS: A total of 92 patients were equally matched across both cohorts, with a median follow-up of 37 months for the SRS group and 27.5 months for those observed. The SRS cohort exhibited superior tumor control over observation across 3, 5, and 8 years, achieving a 100% control rate vs 47.9%, 40.1%, and 34.3% for the observation group at these time intervals, respectively ( P < .001). Serviceable hearing preservation rates were comparable between the 2 groups throughout 3, 5, and 7 years (72.9% for SRS vs 65.4% for observation at 3 years; P = .86). Moreover, SRS management correlated with a lower incidence of vestibular symptoms (odds ratio = 0.11, P = .002), with no significant disparity in the deterioration of cranial nerve (CN) V or CN VII functions. Notably, the likelihood of experiencing any CN impairment was significantly diminished in the SRS cohort (odds ratio = 0.47, P = .04). CONCLUSION: For patients with Koos grade II VS, SRS offers superior tumor control rate and a lower risk of CN dysfunction without sacrificing hearing preservation.
659 A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors
Maziarz, Richard T, Yuan, Yuan , Krishnamurthy, Anuradha , Isaacs, James , Cairo, Mitchell S. , Cao, Felicia , Advani, Pooja , Locke, Kenneth W., WETZEL, J. M., Klichinsky, Michael , Condamine, Thomas , Sohal, Davendra , Abdou, Yara George , Pohlmann, Paula R. , Maziarz, Richard Thomas , Murthy, Hemant S. , Reiss, Kim A. , He, Aiwu Ruth , Blumenthal, Daniel J. , Locke, Kenneth, Wetzel, Jeanette, Kennedy, Eugene Paul

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A756-A756

10.1136/jitc-2024-sitc2024.0659 Get It

Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study
Flanagan, Kevin C. , Earls, Jon, Hiken, Jeffrey, Wellinghoff, Rachel L., Ponder, Michelle, McLeod, Howard L. , Westra, William H. , Vavinskaya, Vera , Sutton, Leisa , Deichaite, Ida , Macdonald, O. Kenneth, Welaya, Karim, Wade, James L. , Azzi, Georges, Pippas, Andrew W., Slim, Jennifer N. , Bank, Bruce, Sui, Xingwei, Kossman, Steven E., Shenkenberg, Todd D., Alexander, Warren L., Price, Katharine A. , Messina, D. , Glasscock, Jarret , Adkins, Douglas, Ley, Jessica C. , Colevas, Alexander Dimitrios , Cohen, Ezra E.W. , Duncavage, Eric James

Mayo Clinic

Journal for ImmunoTherapy of Cancer | November 3, 2024 | Volume: 12 | Issue: 11 | Pages: e009573

10.1136/jitc-2024-009573 | PMID 39489541 Get It

Background Despite advances in cancer care and detection, >65% of patients with squamous cell cancer of the head and neck (HNSCC) will develop recurrent and/or metastatic disease. The prognosis for these patients is poor with a 5-year overall survival of 39%. Recent treatment advances in immunotherapy, including immune checkpoint inhibitors like pembrolizumab and nivolumab, have resulted in clinical benefit in a subset of patients. There is a critical clinical need to identify patients who benefit from these antiprogrammed cell death protein 1 (anti-PD-1) immune checkpoint inhibitors. Methods Here, we report findings from a multicenter observational study, PREDicting immunotherapy efficacy from Analysis of Pre-treatment Tumor biopsies (PREDAPT), conducted across 17 US healthcare systems. PREDAPT aimed to validate OncoPrism-HNSCC, a clinical biomarker assay predictive of disease control in patients with recurrent or metastatic HNSCC treated with anti-PD-1 immune checkpoint inhibitors as a single agent (monotherapy) and in combination with chemotherapy (chemo-immunotherapy). The test used RNA-sequencing data and machine learning models to score each patient and place them into groups of low, medium, or high. Results The OncoPrism-HNSCC prediction significantly correlated with disease control in both the monotherapy cohort (n=62, p=0.004) and the chemo-immunotherapy cohort (n=50, p=0.01). OncoPrism-HNSCC also significantly predicted progression-free survival in both cohorts (p=0.015 and p=0.037, respectively). OncoPrism-HNSCC had more than threefold higher specificity than programmed death-ligand 1 combined positive score and nearly fourfold higher sensitivity than tumor mutational burden for predicting disease control. Conclusions Here, we demonstrate the clinical validity of the OncoPrism-HNSCC assay in identifying patients with disease control in response to anti-PD-1 immune checkpoint inhibitors. Trial registration number NCT04510129.
S7 Identifying Diagnostic Patterns for Exocrine Pancreatic Insufficiency in Adults With Chronic or Recurrent Acute Pancreatitis: Findings From the PACT-CP Registry
Pannala, Rahul , Benipal, P, Buch, Kenneth L., Pack, Jennifer, Twal, Janine, Barkin, Jodie A. , Whitcomb, David C.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S5-S5

10.14309/01.ajg.0001028396.67077.34 Get It